Cabaletta Bio

$15.53
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.58 (+3.88%) Today

$0.00 (0.00%) As of 6:01 PM EST after-hours

Why Robinhood?

You can buy or sell Cabaletta Bio and other stocks, options, and ETFs commission-free!

About CABA

Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA. The listed name for CABA is Cabaletta Bio, Inc. Common Stock.

CEO

Steven Nichtberger

Employees

Headquarters

Philadelphia, Pennsylvania

Founded

2017

Market Cap

373.58M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

57.06K

High Today

$15.72

Low Today

$15.00

Open Price

$15.00

Volume

31.12K

52 Week High

$19.63

52 Week Low

$5.51

Collections

CABA Earnings

-$0.65

-$0.43

-$0.22

$0.00

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Mar 29, Pre-Market